[5] [6] The American College of Cardiology, American Heart Association, and American Diabetes Association now recommend GLP-1 receptor agonists with proven cardiovascular benefit for patients with type 2 diabetes and established atherosclerotic cardiovascular disease, regardless of baseline hemoglobin A1c levels
[9] A standard ladder calibrated for the average trial participant will therefore overshoot for a meaningful share of women, delivering more weight loss than they wanted along with more nausea than anyone wants
From there, we create a plan that outlines everything from dosage to treatment duration
According to NICE guidelines, these medications should be prescribed only as part of a specialist weight management service (Tier 3 or 4), not as standalone treatment
But from a purely clinical standpoint, semaglutide is typically the better first choice for most patients seeking weight loss